logo
All about ‘yield curves' – and the big move for stocks they're pointing to in 2025

All about ‘yield curves' – and the big move for stocks they're pointing to in 2025

New York Post21-07-2025
In my 50-plus years of running money, I've noticed that the biggest market moves come from factors that have gone unnoticed – and right now, there's a doozy lurking under the table.
Amid all the tariff tumult of the past few months, the global yield curve has been quietly re-steepening. Also note that the previously long-watched US-based yield curve – which investors lately (and wrongly) have been ignoring – has been doing the same.
So what's a yield curve, again? It's a graph showing government bond yields from 3-month to 10-year, left to right. When long-term rates top short rates, the curve slopes upward — and is deemed 'steep' and historically bullish. When short-term rates top long, it is 'inverted'— an historically fairly reliable though imperfect recession warning.
Advertisement
4 The biggest market moves come from factors that have gone unnoticed – and right now, there's a doozy lurking under the table.
AFP via Getty Images
Why is that? Like a dashboard indicator, the yield curve usually predicts bank lending trends. Banks use short-term deposits to fund long-term loans — pocketing the spread. Borrow at one rate, lend at a higher rate. Steep curves mean bigger profits, so banks lend eagerly, spurring growth.
Meanwhile, inverted curves — when short-term rates top long — shrink loan profitability. Banks lend less. Since economies rely hugely on loans to finance growth — from building inventory to funding expansion — GDP gets squashed.
Advertisement
For decades, the US yield curve rarely misfired, becoming a lodestar for investors. But like assuming a car's dash is reality, they ignored its 'under the hood' function — the lending. It worked until it didn't.
After global stocks' 2022 decline, yield curves inverted globally. Recession fears surged. Investors gnashed. Yet lending grew. US, eurozone and global GDP expanded. Pockets of contraction like Germany arose but were rare. Stocks bulled upward.
Investors were befuddled. The curve remained inverted in 2023 and through most of 2024, with stocks rising, GDP growing. Pundits scratched their heads, then got bored, ignoring and deeming it 'broken.' It seems they never asked: Why did it 'break'?
4 Amid all the tariff tumult of the past few months, the global yield curve has been quietly re-steepening.
Advertisement
Under the hood, banks held tons of ultra-low-rate, COVID-era deposits. In 2020, US bank deposits ballooned 20.8% from the year earlier and another 11.7% in 2021. They stayed elevated through 2022 and 2023, echoing global trends.
In other words: Banks didn't need to borrow to lend. They needn't compete for deposits by raising deposit rates. That stash of low-cost deposits kept lending profitable even as the Fed hiked to highs of 5.5% alongside other central banks globally.
Now, unseen, yield curves flipped positive, aiding global loan profits. This stems from short-term rate cuts (most heavily overseas – and rising long-term rates (which most wrongly fear, and which are also bullish).
Money flows globally between most nations, so I always monitor a GDP-weighted global yield curve. Last July, it was down 0.55 percentage points — inverted. A few months before that it was down nearly a full point. Now? It has flipped to positive 0.50 points — a quiet, nearly 1.5-point lending boost in slightly over a year. It is both bullish and explains recent trends.
Advertisement
4 A GDP-weighted global yield curve can explain recent trends.
AP
America's curve improved but remains basically flat – down 0.07 points. But Britain flipped from down 0.99 points a year ago to positive 0.35 points now. Continental Europe's shifted more — from down 0.47 to up 1.03!
Stocks show it matters: Regionally the MSCI Europe clocked early new highs and sits up 22% year to date. The non-US trounces America this year.
Steeper curves favor value stocks (like the eurozone and UK's) over growth stocks (which dominate the US). Eurozone and UK Financials—up 52% and 33%, respectively—quietly lead in 2025, trouncing US Tech's 10%. Why? A bank profit turbocharge! Europe's value-heavy Industrials lead, too. They need lending to finance growth.
4 America's curve improved but remains basically flat – down 0.07 points.
That most observers still ignore the curve is vital. It means stocks haven't yet fully priced in this growing, bullish power. Expect it to help drive stocks higher here and to continue doing the same throughout Europe, the UK and most emerging markets.
Ken Fisher is the founder and executive chairman of Fisher Investments, a four-time New York Times bestselling author, and regular columnist in 21 countries globally.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Stock market today: S&P 500, Nasdaq rise as earnings flood in, jobs data on deck
Stock market today: S&P 500, Nasdaq rise as earnings flood in, jobs data on deck

Yahoo

time13 minutes ago

  • Yahoo

Stock market today: S&P 500, Nasdaq rise as earnings flood in, jobs data on deck

US stocks moved higher on Tuesday, eyeing a bid for more records as investors combed through a fresh rush of corporate earnings and waited for key economic data in a big week on Wall Street. The S&P 500 (^GSPC) rose 0.2% on the heels of narrowly notching a sixth all-time closing high in a row, while the tech-heavy Nasdaq Composite (^IXIC) led the way higher with a 0.4% gain. The Dow Jones Industrial Average (^DJI) was roughly flat. The mood is modestly upbeat as a blockbuster week for markets gets into full swing. The Federal Reserve kicks off its two-day policy meeting on Tuesday, while the JOLTS job openings update for June due later ushers in a series of crucial labor data culminating in Friday's nonfarm payrolls report. Meanwhile, earnings take center stage as before-the-bell reports from Spotify (SPOT), Merck (MRK), and UnitedHealth (UNH) disappointed Wall Street. Some news were better than others: Boeing (BA) shares lifted as the world's largest planemaker's quarterly results topped expectations. After the bell Tuesday, Starbucks (SBUX) earnings will be scrutinized for signs of turnaround progress and of the impact of tariffs. The wave of earnings Tuesday will help set the tone for this week's highlights: results from tech giants Apple (AAPL), Amazon (AMZN), Microsoft (MSFT), and Meta (META). Read more: Full earnings coverage in our live blog Also looming large is President Trump's deadline Friday for trading partners to strike deals or face blanket tariff rates. The Commerce Department's Census Bureau on Tuesday reported a sharp decline in the US goods trade deficit in June as businesses looked to get ahead of tariffs. Hopes for an extension to the US-China trade truce are buoying the likes of AI chipmaker Nvidia's (NVDA) stock. Read more: The latest on Trump's tariffs Trade war fears may have lost their grip on markets, given the S&P 500 (^GSPC) and Nasdaq Composite (^IXIC) only barely managed new records on Monday despite a new US-EU trade deal. On Tuesday's economic docket, Conference Board's July reading on consumer confidence and a S&P CoreLogic print on home prices in May provide a health check on the economy ahead of an update on second quarter GDP later this week, P&G dips as it warns of $1 billion tariff hit Procter & Gamble (PG) stock dipped about 1%, reversing a slight premarket gain, as the company took a cautious approach with its financial outlook while it navigates uncertain consumer sentiment and Trump's tariffs. Yahoo Finance's Brian Sozzi reports: Read the full story here. Tech leads stocks higher at the open The tech-heavy Nasdaq Composite (^IXIC) led US stocks higher at the open on Tuesday morning with a 0.5% gain. Meanwhile, the S&P 500 (^GSPC) rose 0.2% on the heels of notching a sixth all-time closing high in a row on Monday. The Dow Jones Industrial Average (^DJI) opened roughly flat. Investors are digesting a wave of earnings reports and US trade data showing a sharp narrowing in the deficit (as tariffs loom). Meanwhile, they are looking ahead to the JOLTS job openings update for June at 10 a.m. ET. for labor market insight. Major drugmakers mixed amid earnings Of the notable drugmakers reporting earnings Tuesday, AstraZeneca rose almost 2% and Merck fell nearly 4% before the market open. British drugmaker AstraZeneca reported second quarter revenue ahead of expectations Tuesday, with its cancer drugs helping fuel sales for the period. Meanwhile, fellow pharma giant Merck reported earnings below Wall Street's projections, according to Bloomberg consensus data, and revenue from its HPV vaccine Gardasil was also less than expected amid continued headwinds in China. Investors are also bracing for patents for its drug Keytruda (which accounted for roughly half of its second quarter revenue) to expire in 2028. Also on Tuesday, Danish drugmaker Novo Nordisk (NVO) plummeted roughly 20%. The firm cut its 2025 revenue and profit outlook, pointing to lower than expected sales growth of its obesity drug Wegovy in the US, ahead of its second quarter earnings results slated for Aug. 6. Trump's DOJ puts companies on notice: Don't evade tariffs The Justice Department is putting American companies on notice that they could be prosecuted if they chose to evade President Trump's tariffs, even as the legality of the president's "Liberation Day" duties remain unsettled in US courts. Yahoo Finance's Alexis Keenan reports: Read more here. Nvidia leads Mag 7 higher on sign of 'enormous pent-up demand' from China Nvidia (NVDA) led the Big Tech "Magnificent Seven" stocks higher on Tuesday before the market open, climbing 1.4%. The gain came after Reuters reported that the AI chipmaker had ordered 300,000 H20 chips from its contract manufacturer TSMC. "This supports our theory that there is enormous pent-up demand for NVDA chips from China right now," Hedgeye Risk Management analyst Felix Wang wrote in a note to clients. Meanwhile, Microsoft (MSFT), Meta (META), and Amazon (AMZN) rose fractionally ahead of their quarterly earnings reports later this week. Apple (AAPL), Google (GOOG), and Tesla (TSLA) traded down less than 1%. Good morning. Here's what's happening today. Economic data: S&P CoreLogic 20-city home price index (May); Conference Board consumer confidence, July; Job Openings and Labor Turnover Survey (June); Dallas Fed services activity (July) Earnings: Boeing (BA), Booking Holdings (BKNG), Caesars (CZR), Cheesecake Factory (CAKE), Merck (MRK), PayPal (PYPL), Procter & Gamble (PG), Spotify (SPOT), Starbucks (SBUX), SoFi (SOFI), UnitedHealth Group (UNH), UPS (UPS), Visa (V) Here are some of the biggest stories you may have missed overnight and early this morning: The market is finally getting what it wants 35 charts explain markets and the economy right now UnitedHealth stock falls after reporting mixed Q2 earnings Sarepta stock soars as FDA reverses course on gene therapy pause Spotify stock slides after Q2 earnings and revenue miss Trump's DOJ puts companies on notice on tariffs US, EU rush to clinch final details and lock in trade deal Apple to Shutter a Retail Store in China for the First Time Ever Stellantis faces $1.7B hit from US tariffs this year Trending tickers: UPS, Whilepool and Royal Caribbean Here are some top stocks trending on Yahoo Finance in premarket trading: UPS (UPS) stock fell over 2% before the bell on Tuesday after reporting a drop in second-quarter profit and revenue, as demand took a hit from new "de minimis" tariffs on low-value Chinese shipments and mounting risks from President Donald Trump's trade policies. Whirlpool (WHR) stock fell premarket on Tuesday. after the appliance maker slashed its earnings outlook the day prior. Royal Caribbean (RCL) stock rose 4% before the bell after raising its annual profit forecast on Tuesday, banking on resilient demand for the cruise operator's high-end private island destinations and premium sailings. The market is finally getting what it wants Wall Street's busiest week of the summer is turning out to be an inflection point. Yahoo Finance's Hamza Shaban explains why in today's Morning Brief: Read more here. Spotify stock sinks after Q2 earnings miss Spotify (SPOT) shares fell as much as 10% in early premarket trading Tuesday after the company missed second quarter earnings and revenue expectations. The results follow a remarkable 120% rally over the past year, as the stock rebounded from 2022 lows on the back of price hikes, cost cuts, and investor enthusiasm for AI and advertising. Spotify hit a record high of $738.45 earlier this month, but shares slid to around $635 immediately following the results. Spotify reported second quarter revenue of €4.19 billion ($4.86 billion), missing analyst expectations of €4.27 billion, though up from €3.81 billion in the same period last year. The company posted an adjusted loss of €0.42 ($0.49) per share, sharply missing forecasts for a profit of €1.97 and down from earnings of €1.33 in Q2 2024. "Outsized currency movements during the quarter impacted reported revenue by €104 million vs. guidance," the company said in the earnings release. Operating income also fell short of expectations in the quarter, though subscriber metrics for both premium and ad-supported tiers came in ahead of estimates. Gross margins of 31.5% came in as expected. Spotify's massive rally heading into the earnings report was fueled by a sweeping business overhaul, including layoffs, leadership changes, and a pullback from costly podcast exclusivity. After spending $1 billion to build out its podcast business, the company has since scaled back and narrowed its focus. Still, it remains committed to the medium, paying over $100 million to creators in Q1 alone, including high-profile names like Joe Rogan and Alex Cooper. Read more here. UnitedHealth stock slips after mixed Q2 results Shares of UnitedHealth Group (UNH) fell nearly 3% after its quarterly results before the bell painted a mixed picture. Yahoo Finance's Anjalee Khemlani reports: Read more here. Sarepta stock rockets higher after FDA greenlight Shares in drugmaker Sarepta (SRPT) rocketed up over 30% in premarket after the embattled company got the FDA's go-ahead to resume shipments of its Elevdis gene therapy. The greenlight comes after Sarepta put a voluntary pause on shipments for some patients while the US regulator reviewed its safety following deaths. The FDA on Monday recommended that the compa lift that halt. Sarepta's stock is poised to build on a 16% gain on Monday, continuing a recent volatile spell triggered by changing fortunes for its best-selling product. AP reports: Read more here. Nvidia orders 300,000 H20 chips from TSMC to satiate Chinese demand Reuters reports: Nvidia placed orders for 300,000 H20 chipsets with contract manufacturer TSMC last week, two sources said, with one of them adding that strong Chinese demand had led the U.S. firm to change its mind about just relying on its existing stockpile. Read more here. Oil maintains gains with tariffs and OPEC+ supply in sight Oil maintained gains following Trump putting pressure on Russia over the war in Ukraine with economic sanctions against Putin's government on the table. Bloomberg reports: Read more here. P&G dips as it warns of $1 billion tariff hit Procter & Gamble (PG) stock dipped about 1%, reversing a slight premarket gain, as the company took a cautious approach with its financial outlook while it navigates uncertain consumer sentiment and Trump's tariffs. Yahoo Finance's Brian Sozzi reports: Read the full story here. Procter & Gamble (PG) stock dipped about 1%, reversing a slight premarket gain, as the company took a cautious approach with its financial outlook while it navigates uncertain consumer sentiment and Trump's tariffs. Yahoo Finance's Brian Sozzi reports: Read the full story here. Tech leads stocks higher at the open The tech-heavy Nasdaq Composite (^IXIC) led US stocks higher at the open on Tuesday morning with a 0.5% gain. Meanwhile, the S&P 500 (^GSPC) rose 0.2% on the heels of notching a sixth all-time closing high in a row on Monday. The Dow Jones Industrial Average (^DJI) opened roughly flat. Investors are digesting a wave of earnings reports and US trade data showing a sharp narrowing in the deficit (as tariffs loom). Meanwhile, they are looking ahead to the JOLTS job openings update for June at 10 a.m. ET. for labor market insight. The tech-heavy Nasdaq Composite (^IXIC) led US stocks higher at the open on Tuesday morning with a 0.5% gain. Meanwhile, the S&P 500 (^GSPC) rose 0.2% on the heels of notching a sixth all-time closing high in a row on Monday. The Dow Jones Industrial Average (^DJI) opened roughly flat. Investors are digesting a wave of earnings reports and US trade data showing a sharp narrowing in the deficit (as tariffs loom). Meanwhile, they are looking ahead to the JOLTS job openings update for June at 10 a.m. ET. for labor market insight. Major drugmakers mixed amid earnings Of the notable drugmakers reporting earnings Tuesday, AstraZeneca rose almost 2% and Merck fell nearly 4% before the market open. British drugmaker AstraZeneca reported second quarter revenue ahead of expectations Tuesday, with its cancer drugs helping fuel sales for the period. Meanwhile, fellow pharma giant Merck reported earnings below Wall Street's projections, according to Bloomberg consensus data, and revenue from its HPV vaccine Gardasil was also less than expected amid continued headwinds in China. Investors are also bracing for patents for its drug Keytruda (which accounted for roughly half of its second quarter revenue) to expire in 2028. Also on Tuesday, Danish drugmaker Novo Nordisk (NVO) plummeted roughly 20%. The firm cut its 2025 revenue and profit outlook, pointing to lower than expected sales growth of its obesity drug Wegovy in the US, ahead of its second quarter earnings results slated for Aug. 6. Of the notable drugmakers reporting earnings Tuesday, AstraZeneca rose almost 2% and Merck fell nearly 4% before the market open. British drugmaker AstraZeneca reported second quarter revenue ahead of expectations Tuesday, with its cancer drugs helping fuel sales for the period. Meanwhile, fellow pharma giant Merck reported earnings below Wall Street's projections, according to Bloomberg consensus data, and revenue from its HPV vaccine Gardasil was also less than expected amid continued headwinds in China. Investors are also bracing for patents for its drug Keytruda (which accounted for roughly half of its second quarter revenue) to expire in 2028. Also on Tuesday, Danish drugmaker Novo Nordisk (NVO) plummeted roughly 20%. The firm cut its 2025 revenue and profit outlook, pointing to lower than expected sales growth of its obesity drug Wegovy in the US, ahead of its second quarter earnings results slated for Aug. 6. Trump's DOJ puts companies on notice: Don't evade tariffs The Justice Department is putting American companies on notice that they could be prosecuted if they chose to evade President Trump's tariffs, even as the legality of the president's "Liberation Day" duties remain unsettled in US courts. Yahoo Finance's Alexis Keenan reports: Read more here. The Justice Department is putting American companies on notice that they could be prosecuted if they chose to evade President Trump's tariffs, even as the legality of the president's "Liberation Day" duties remain unsettled in US courts. Yahoo Finance's Alexis Keenan reports: Read more here. Nvidia leads Mag 7 higher on sign of 'enormous pent-up demand' from China Nvidia (NVDA) led the Big Tech "Magnificent Seven" stocks higher on Tuesday before the market open, climbing 1.4%. The gain came after Reuters reported that the AI chipmaker had ordered 300,000 H20 chips from its contract manufacturer TSMC. "This supports our theory that there is enormous pent-up demand for NVDA chips from China right now," Hedgeye Risk Management analyst Felix Wang wrote in a note to clients. Meanwhile, Microsoft (MSFT), Meta (META), and Amazon (AMZN) rose fractionally ahead of their quarterly earnings reports later this week. Apple (AAPL), Google (GOOG), and Tesla (TSLA) traded down less than 1%. Nvidia (NVDA) led the Big Tech "Magnificent Seven" stocks higher on Tuesday before the market open, climbing 1.4%. The gain came after Reuters reported that the AI chipmaker had ordered 300,000 H20 chips from its contract manufacturer TSMC. "This supports our theory that there is enormous pent-up demand for NVDA chips from China right now," Hedgeye Risk Management analyst Felix Wang wrote in a note to clients. Meanwhile, Microsoft (MSFT), Meta (META), and Amazon (AMZN) rose fractionally ahead of their quarterly earnings reports later this week. Apple (AAPL), Google (GOOG), and Tesla (TSLA) traded down less than 1%. Good morning. Here's what's happening today. Economic data: S&P CoreLogic 20-city home price index (May); Conference Board consumer confidence, July; Job Openings and Labor Turnover Survey (June); Dallas Fed services activity (July) Earnings: Boeing (BA), Booking Holdings (BKNG), Caesars (CZR), Cheesecake Factory (CAKE), Merck (MRK), PayPal (PYPL), Procter & Gamble (PG), Spotify (SPOT), Starbucks (SBUX), SoFi (SOFI), UnitedHealth Group (UNH), UPS (UPS), Visa (V) Here are some of the biggest stories you may have missed overnight and early this morning: The market is finally getting what it wants 35 charts explain markets and the economy right now UnitedHealth stock falls after reporting mixed Q2 earnings Sarepta stock soars as FDA reverses course on gene therapy pause Spotify stock slides after Q2 earnings and revenue miss Trump's DOJ puts companies on notice on tariffs US, EU rush to clinch final details and lock in trade deal Apple to Shutter a Retail Store in China for the First Time Ever Stellantis faces $1.7B hit from US tariffs this year Economic data: S&P CoreLogic 20-city home price index (May); Conference Board consumer confidence, July; Job Openings and Labor Turnover Survey (June); Dallas Fed services activity (July) Earnings: Boeing (BA), Booking Holdings (BKNG), Caesars (CZR), Cheesecake Factory (CAKE), Merck (MRK), PayPal (PYPL), Procter & Gamble (PG), Spotify (SPOT), Starbucks (SBUX), SoFi (SOFI), UnitedHealth Group (UNH), UPS (UPS), Visa (V) Here are some of the biggest stories you may have missed overnight and early this morning: The market is finally getting what it wants 35 charts explain markets and the economy right now UnitedHealth stock falls after reporting mixed Q2 earnings Sarepta stock soars as FDA reverses course on gene therapy pause Spotify stock slides after Q2 earnings and revenue miss Trump's DOJ puts companies on notice on tariffs US, EU rush to clinch final details and lock in trade deal Apple to Shutter a Retail Store in China for the First Time Ever Stellantis faces $1.7B hit from US tariffs this year Trending tickers: UPS, Whilepool and Royal Caribbean Here are some top stocks trending on Yahoo Finance in premarket trading: UPS (UPS) stock fell over 2% before the bell on Tuesday after reporting a drop in second-quarter profit and revenue, as demand took a hit from new "de minimis" tariffs on low-value Chinese shipments and mounting risks from President Donald Trump's trade policies. Whirlpool (WHR) stock fell premarket on Tuesday. after the appliance maker slashed its earnings outlook the day prior. Royal Caribbean (RCL) stock rose 4% before the bell after raising its annual profit forecast on Tuesday, banking on resilient demand for the cruise operator's high-end private island destinations and premium sailings. Here are some top stocks trending on Yahoo Finance in premarket trading: UPS (UPS) stock fell over 2% before the bell on Tuesday after reporting a drop in second-quarter profit and revenue, as demand took a hit from new "de minimis" tariffs on low-value Chinese shipments and mounting risks from President Donald Trump's trade policies. Whirlpool (WHR) stock fell premarket on Tuesday. after the appliance maker slashed its earnings outlook the day prior. Royal Caribbean (RCL) stock rose 4% before the bell after raising its annual profit forecast on Tuesday, banking on resilient demand for the cruise operator's high-end private island destinations and premium sailings. The market is finally getting what it wants Wall Street's busiest week of the summer is turning out to be an inflection point. Yahoo Finance's Hamza Shaban explains why in today's Morning Brief: Read more here. Wall Street's busiest week of the summer is turning out to be an inflection point. Yahoo Finance's Hamza Shaban explains why in today's Morning Brief: Read more here. Spotify stock sinks after Q2 earnings miss Spotify (SPOT) shares fell as much as 10% in early premarket trading Tuesday after the company missed second quarter earnings and revenue expectations. The results follow a remarkable 120% rally over the past year, as the stock rebounded from 2022 lows on the back of price hikes, cost cuts, and investor enthusiasm for AI and advertising. Spotify hit a record high of $738.45 earlier this month, but shares slid to around $635 immediately following the results. Spotify reported second quarter revenue of €4.19 billion ($4.86 billion), missing analyst expectations of €4.27 billion, though up from €3.81 billion in the same period last year. The company posted an adjusted loss of €0.42 ($0.49) per share, sharply missing forecasts for a profit of €1.97 and down from earnings of €1.33 in Q2 2024. "Outsized currency movements during the quarter impacted reported revenue by €104 million vs. guidance," the company said in the earnings release. Operating income also fell short of expectations in the quarter, though subscriber metrics for both premium and ad-supported tiers came in ahead of estimates. Gross margins of 31.5% came in as expected. Spotify's massive rally heading into the earnings report was fueled by a sweeping business overhaul, including layoffs, leadership changes, and a pullback from costly podcast exclusivity. After spending $1 billion to build out its podcast business, the company has since scaled back and narrowed its focus. Still, it remains committed to the medium, paying over $100 million to creators in Q1 alone, including high-profile names like Joe Rogan and Alex Cooper. Read more here. Spotify (SPOT) shares fell as much as 10% in early premarket trading Tuesday after the company missed second quarter earnings and revenue expectations. The results follow a remarkable 120% rally over the past year, as the stock rebounded from 2022 lows on the back of price hikes, cost cuts, and investor enthusiasm for AI and advertising. Spotify hit a record high of $738.45 earlier this month, but shares slid to around $635 immediately following the results. Spotify reported second quarter revenue of €4.19 billion ($4.86 billion), missing analyst expectations of €4.27 billion, though up from €3.81 billion in the same period last year. The company posted an adjusted loss of €0.42 ($0.49) per share, sharply missing forecasts for a profit of €1.97 and down from earnings of €1.33 in Q2 2024. "Outsized currency movements during the quarter impacted reported revenue by €104 million vs. guidance," the company said in the earnings release. Operating income also fell short of expectations in the quarter, though subscriber metrics for both premium and ad-supported tiers came in ahead of estimates. Gross margins of 31.5% came in as expected. Spotify's massive rally heading into the earnings report was fueled by a sweeping business overhaul, including layoffs, leadership changes, and a pullback from costly podcast exclusivity. After spending $1 billion to build out its podcast business, the company has since scaled back and narrowed its focus. Still, it remains committed to the medium, paying over $100 million to creators in Q1 alone, including high-profile names like Joe Rogan and Alex Cooper. Read more here. UnitedHealth stock slips after mixed Q2 results Shares of UnitedHealth Group (UNH) fell nearly 3% after its quarterly results before the bell painted a mixed picture. Yahoo Finance's Anjalee Khemlani reports: Read more here. Shares of UnitedHealth Group (UNH) fell nearly 3% after its quarterly results before the bell painted a mixed picture. Yahoo Finance's Anjalee Khemlani reports: Read more here. Sarepta stock rockets higher after FDA greenlight Shares in drugmaker Sarepta (SRPT) rocketed up over 30% in premarket after the embattled company got the FDA's go-ahead to resume shipments of its Elevdis gene therapy. The greenlight comes after Sarepta put a voluntary pause on shipments for some patients while the US regulator reviewed its safety following deaths. The FDA on Monday recommended that the compa lift that halt. Sarepta's stock is poised to build on a 16% gain on Monday, continuing a recent volatile spell triggered by changing fortunes for its best-selling product. AP reports: Read more here. Shares in drugmaker Sarepta (SRPT) rocketed up over 30% in premarket after the embattled company got the FDA's go-ahead to resume shipments of its Elevdis gene therapy. The greenlight comes after Sarepta put a voluntary pause on shipments for some patients while the US regulator reviewed its safety following deaths. The FDA on Monday recommended that the compa lift that halt. Sarepta's stock is poised to build on a 16% gain on Monday, continuing a recent volatile spell triggered by changing fortunes for its best-selling product. AP reports: Read more here. Nvidia orders 300,000 H20 chips from TSMC to satiate Chinese demand Reuters reports: Nvidia placed orders for 300,000 H20 chipsets with contract manufacturer TSMC last week, two sources said, with one of them adding that strong Chinese demand had led the U.S. firm to change its mind about just relying on its existing stockpile. Read more here. Reuters reports: Nvidia placed orders for 300,000 H20 chipsets with contract manufacturer TSMC last week, two sources said, with one of them adding that strong Chinese demand had led the U.S. firm to change its mind about just relying on its existing stockpile. Read more here. Oil maintains gains with tariffs and OPEC+ supply in sight Oil maintained gains following Trump putting pressure on Russia over the war in Ukraine with economic sanctions against Putin's government on the table. Bloomberg reports: Read more here. Oil maintained gains following Trump putting pressure on Russia over the war in Ukraine with economic sanctions against Putin's government on the table. Bloomberg reports: Read more here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors
Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors

Yahoo

time13 minutes ago

  • Yahoo

Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors

We recently published . Esperion Therapeutics, Inc. (NASDAQ:ESPR) is one of the best-performing stocks on Monday. Esperion Therapeutics extended its winning streak to a fifth consecutive day on Monday, adding 5.3 percent to close at $1.59 apiece as investors gobbled up shares ahead of its earnings release amid reports that it was set to be acquired by a Japan-based pharmaceutical company. According to a post by @rumourbuyouts on X, pharmaceutical firm Otsuka is said to be in talks to fully acquire Esperion Therapeutics, Inc. (NASDAQ:ESPR) in a deal that could potentially be valued $900 million. The post added that the two companies are set to meet in August to discuss a deal. Copyright: lightwise / 123RF Stock Photo Based on the social media handle, @rumourbuyouts is currently based in Japan and only has 177 followers. Meanwhile, Esperion Therapeutics, Inc. (NASDAQ:ESPR) said that it is scheduled to release the results of its second quarter earnings performance before market open on August 5, Tuesday. While we acknowledge the potential of ESPR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Building materials maker CRH to acquire Eco Material for $2.1 billion
Building materials maker CRH to acquire Eco Material for $2.1 billion

Yahoo

time13 minutes ago

  • Yahoo

Building materials maker CRH to acquire Eco Material for $2.1 billion

(Reuters) -Building materials maker CRH said on Tuesday it has agreed to acquire Eco Material Technologies, a supplier of supplementary cementitious materials, for $2.1 billion to expand its presence in North America. Dublin, Ireland-based CRH operates through two regional divisions Americas and International, of which the Americas business brings in 65% of revenues as per its latest annual filing, and includes the production of aggregates, cement, ready-mixed concrete and asphalt used in construction. As traditional cement production is responsible for around 8% of global CO2 emissions, the industry has been making the switch to low-carbon alternatives, through investments, joint ventures and mergers. With the takeover of the Utah-based near-zero carbon cement producer Eco Material, CRH also acquires its national network of fresh and harvested fly ash, pozzolans, synthetic gypsum and green cement operations. "This transaction secures the long-term supply of critical materials for future growth and puts CRH at the forefront of the transition to next generation cement and concrete," CRH chief executive Jim Mintern said. CRH, which has its presence across 28 countries, said it plans to fund the deal, expected to close in 2025, with cash on hand. The business will operate as Eco Material Technologies, a CRH Company. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store